论文部分内容阅读
目的动态观察CD3AK细胞输往对大肠癌术后早期机体免疫功能的影响。方法将25例大肠癌患者分为A、B两组。A组13例，术后第1天开始使用CD3AK细胞治疗，共2个周期。B组12例，未用CD3AK细胞治疗。另以大肠良性肿瘤患者作为对照组（C组）。结果A组患者的细胞免疫指标（CD3、CD4、CD4／CD8、NKC、IL-2R、T淋巴细胞转化率）及体液免疫指标（sIL－2R、TNF－α）在术后第1周开始迅速恢复且维持在高水平状态（P＜0．05），而B组术后细胞免疫及体液免疫功能指标在术后第一周时较术前明显降低（P＜0．05）。A、B两组术后同期同指标相比较差异有显著性（P＜0.05）。C组外周血单个核细胞的分布及体液免疫功能指标在术前、术后相比较差异无显著性（P＞0.05），但均比A、B组高。结论应用CD3AK细胞治疗可纠正、恢复及提高大肠癌患者术后早期机体的细胞免疫和体液免疫功能。
Objective To observe the effect of CD3AK cells on the early postoperative immune function of colorectal cancer. Methods 25 patients with colorectal cancer were divided into A and B groups. In group A, 13 patients were treated with CD3AK cells on the first postoperative day for a total of 2 cycles. 12 patients in group B were not treated with CD3AK cells. Another group of patients with benign colorectal cancer as a control group (C). Results The cellular immune parameters (CD3, CD4, CD4/CD8, NKC, IL-2R, and T lymphocyte conversion rate) and humoral immunity index (sIL-2R, TNF-α) in group A began rapidly at the first postoperative week. Recovery and maintained at a high level (P <0.05), and the index of cellular immunity and humoral immune function in group B decreased significantly in the first postoperative period compared with preoperative (P <0.05). There was significant difference between the two groups in the same period of postoperative A and B groups (P<0.05). There was no significant difference in the distribution of peripheral blood mononuclear cells and humoral immune function between group C and preoperative (P>0.05), but higher than that of group A and B. Conclusion The application of CD3AK cell therapy can correct, restore and improve the cellular immunity and humoral immunity of patients with colorectal cancer early after surgery.